The TRanslational Initiative to DE-risk NeuroTherapeutics (TRIDENT) is revolutionizing preclinical trials for the treatments of neurodegenerative diseases with a $24M grant from the Government of Canada's New Frontiers In Research program.

TRIDENT leverages innovative cognition testing, advanced molecular and imaging techniques, and existing industry and academic partnerships to identify and predict highly successful drug candidates.

By transforming the nature of preclinical evaluation, our platform will radically
improve our ability to identify disease-modifying therapies leading to a world without brain disease.

TRIDENT Preclinical Trials

Org chart

Teams

Offices

TRIDENT Preclinical Trials

Org chart

Teams

Offices

Related companies